{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T02:21:54Z","timestamp":1788142914032,"version":"build-2803163510"},"reference-count":96,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T00:00:00Z","timestamp":1641945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Exactly 70 years ago [1951] mercaptopurine was discovered by Gertrude Elion as a novel treatment option for acute leukaemia. A total of three thiopurines (also thioguanine [1950] and azathioprine [1957]) were developed over time. These immunosuppressive drugs were also successfully introduced a few decades later to prevent rejection of transplanted organs and to treat several autoimmune diseases. For her discovery of thiopurines and other antimetabolite drugs, in 1988 Elion was rewarded, together with George Hitchings and James Black, with the Nobel Prize in Physiology or Medicine. Important steps have been made in recent years to unravel its metabolism, mode of action and pharmacogenetics. Today thiopurine [based] therapy remains an essential immunosuppressive approach in treating patients with inflammatory bowel disease.<\/jats:p>","DOI":"10.1093\/ecco-jcc\/jjac004","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T20:14:42Z","timestamp":1641932082000},"page":"1177-1183","source":"Crossref","is-referenced-by-count":17,"title":["The Thiopurine Tale: An Unexpected Journey"],"prefix":"10.1093","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8755-9146","authenticated-orcid":false,"given":"Femke","family":"Crouwel","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam , Amsterdam , the Netherland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J C","family":"Buiter","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam , Amsterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanne K","family":"de Boer","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam , Amsterdam , the Netherland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,12]]},"reference":[{"key":"2022080417290500900_CIT0001","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1126\/science.2649979","article-title":"The purine path to chemotherapy","volume":"244","author":"Elion","year":"1989","journal-title":"Science"},{"key":"2022080417290500900_CIT0002","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1634\/theoncologist.11-9-966","article-title":"Autobiography of Gertrude B. Elion, The Nobel Prize in Physiology or Medicine 1988","volume":"11","year":"2006","journal-title":"Oncologist"},{"key":"2022080417290500900_CIT0003","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1093\/eurheartj\/ehaa124","article-title":"George H. Hitchings and Gertrude B. Elion","volume":"41","author":"Nicholls","year":"2020","journal-title":"Eur Heart J"},{"key":"2022080417290500900_CIT0004","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.clinthera.2018.01.008","article-title":"A tribute to Gertrude Belle Elion on the 100th anniversary of her birth","volume":"40","author":"Shader","year":"2018","journal-title":"Clin Ther"},{"key":"2022080417290500900_CIT0005","first-page":"74","article-title":"The relation of p-aminobenzoic acid to the mechanism of the action of sulphanilamide","volume":"21","author":"Woods","year":"1940","journal-title":"Br J Exp Pathol."},{"key":"2022080417290500900_CIT0006","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(00)72741-3","article-title":"A rational approach to research in chemotherapy","volume":"235","author":"Fildes","year":"1940","journal-title":"Lancet"},{"key":"2022080417290500900_CIT0007","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0021-9258(19)77771-0","article-title":"Antagonists of nucleic acid derivatives: VI. Purines","volume":"192","author":"Elion","year":"1951","journal-title":"J Biol Chem"},{"key":"2022080417290500900_CIT0008","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1749-6632.1954.tb40019.x","article-title":"The toxic effects of 6-mercaptopurine and related compounds","volume":"60","author":"Philips","year":"1954","journal-title":"Ann N Y Acad Sci"},{"key":"2022080417290500900_CIT0009","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood.V8.11.965.965","article-title":"Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases","volume":"8","author":"Burchenal","year":"1953","journal-title":"Blood"},{"key":"2022080417290500900_CIT0010","first-page":"588","article-title":"The metabolic fate of the methylnitroimidazole moiety of azathioprine in the rat","volume":"187","author":"De Miranda","year":"1973","journal-title":"J Pharmacol Exp Ther"},{"key":"2022080417290500900_CIT0011","first-page":"99","article-title":"Clinical and hematologic study of 6[(1-methyl-4-nitro-5-imidazolyl)thio]-purine (B.W.57-322) and related compounds","volume":"14","author":"Rundles","year":"1961","journal-title":"Cancer Chemother Rep"},{"key":"2022080417290500900_CIT0012","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF02220605","article-title":"The clinical pharmacology of 6-mercaptopurine","volume":"43","author":"Lennard","year":"1992","journal-title":"Eur J Clin Pharmacol"},{"key":"2022080417290500900_CIT0013","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0145-2126(94)90159-7","article-title":"The cytotoxicity of thioguanine vs mercaptopurine in acute lymphoblastic leukemia","volume":"18","author":"Adamson","year":"1994","journal-title":"Leuk Res"},{"key":"2022080417290500900_CIT0014","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0145-2126(94)90160-0","article-title":"Mercaptopurine vs thioguanine for the treatment of acute lymphoblastic leukemia","volume":"18","author":"Evans","year":"1994","journal-title":"Leuk Res"},{"key":"2022080417290500900_CIT0015","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S0140-6736(94)92400-7","article-title":"Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia","volume":"343","author":"Lilleyman","year":"1994","journal-title":"Lancet"},{"key":"2022080417290500900_CIT0016","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0140-6736(06)69558-5","article-title":"Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial","volume":"368","author":"Vora","year":"2006","journal-title":"Lancet"},{"key":"2022080417290500900_CIT0017","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1182\/blood-2009-07-230656","article-title":"Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children\u2019s Oncology Group CCG-1952 clinical trial","volume":"115","author":"Stork","year":"2010","journal-title":"Blood"},{"key":"2022080417290500900_CIT0018","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2002-08-2372","article-title":"Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92","volume":"102","author":"Harms","year":"2003","journal-title":"Blood"},{"key":"2022080417290500900_CIT0019","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3181\/00379727-99-24281","article-title":"Effect of 6-mercaptopurine on antibody production","volume":"99","author":"Schwartz","year":"1958","journal-title":"Proc Soc Exp Biol Med"},{"key":"2022080417290500900_CIT0020","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0140-6736(60)90343-3","article-title":"The rejection of renal homografts. Inhibition in dogs by 6-mercaptopurine","volume":"1","author":"Calne","year":"1960","journal-title":"Lancet"},{"key":"2022080417290500900_CIT0021","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1749-6632.1962.tb45358.x","article-title":"A study of the effects of drugs in prolonging survival of homologous renal transplants in dogs","volume":"99","author":"Calne","year":"1962","journal-title":"Ann N Y Acad Sci"},{"key":"2022080417290500900_CIT0022","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00000658-196209000-00002","article-title":"Kidney transplantation in modified recipients","volume":"156","author":"Murray","year":"1962","journal-title":"Ann Surg"},{"key":"2022080417290500900_CIT0023","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s002680010124","article-title":"History of clinical transplantation","volume":"24","author":"Starzl","year":"2000","journal-title":"World J Surg"},{"key":"2022080417290500900_CIT0024","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJM196306132682401","article-title":"Prolonged survival of human-kidney homografts by immunosuppressive drug therapy","volume":"268","author":"Murray","year":"1963","journal-title":"N Engl J Med"},{"key":"2022080417290500900_CIT0025","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1111\/j.1600-6143.2009.02705.x","article-title":"Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil","volume":"9","author":"Germani","year":"2009","journal-title":"Am J Transplant"},{"key":"2022080417290500900_CIT0026","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/lt.23566","article-title":"Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation","volume":"19","author":"Lucey","year":"2013","journal-title":"Liver Transplant"},{"key":"2022080417290500900_CIT0027","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.healun.2020.06.024","article-title":"Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: access, formulations, generics, therapeutic drug monitoring, and special populations","volume":"39","author":"Cochrane","year":"2020","journal-title":"J Heart Lung Transplant"},{"key":"2022080417290500900_CIT0028","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJM198005013021801","article-title":"Treatment of Crohn\u2019s disease with 6-mercaptopurine","volume":"302","author":"Present","year":"1980","journal-title":"N Engl J Med"},{"key":"2022080417290500900_CIT0029","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO Guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"14","author":"Torres","year":"2019","journal-title":"J Crohns Colitis"},{"issue":"10","key":"2022080417290500900_CIT0030","first-page":"CD000545","article-title":"Azathioprine or 6-mercaptopurine for induction of remission in Crohn\u2019s disease","volume":"10","author":"Chande","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2022080417290500900_CIT0031","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"2022080417290500900_CIT0032","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/ibd\/izx065","article-title":"Combination immunosuppression in IBD","volume":"24","author":"Bots","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2022080417290500900_CIT0033","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/apt.13994","article-title":"Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease","volume":"45","author":"Strik","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2022080417290500900_CIT0034","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/gut.37.5.674","article-title":"A controlled double blind study of azathioprine in the management of Crohn\u2019s disease","volume":"37","author":"Candy","year":"1995","journal-title":"Gut"},{"key":"2022080417290500900_CIT0035","first-page":"Cd000067","article-title":"Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn\u2019s disease","volume":"10","author":"Chande","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2022080417290500900_CIT0036","doi-asserted-by":"crossref","first-page":"592","DOI":"10.5694\/j.1326-5377.1962.tb20590.x","article-title":"The treatment of chronic ulcerative colitis with 6-mercaptopurine","volume":"49","author":"Bean","year":"1962","journal-title":"Med J Aust"},{"key":"2022080417290500900_CIT0037","first-page":"1711","article-title":"The long-term outcome of ulcerative colitis treated with 6-mercaptopurine","volume":"91","author":"George","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"2022080417290500900_CIT0038","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/BF02156261","article-title":"The role of azathioprine in the management of ulcerative colitis","volume":"33","author":"Lobo","year":"1990","journal-title":"Dis Colon Rectum"},{"key":"2022080417290500900_CIT0039","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/gut.50.4.485","article-title":"The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review","volume":"50","author":"Fraser","year":"2002","journal-title":"Gut"},{"key":"2022080417290500900_CIT0040","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/bmj.4.5945.627","article-title":"Azathioprine in ulcerative colitis: final report on controlled therapeutic trial","volume":"4","author":"Jewell","year":"1974","journal-title":"Br Med J"},{"key":"2022080417290500900_CIT0041","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF01072336","article-title":"Double-blind comparison of the effectiveness of azathioprine and sulfasalazine in idiopathic proctocolitis. Preliminary report","volume":"20","author":"Caprilli","year":"1975","journal-title":"Am J Dig Dis"},{"key":"2022080417290500900_CIT0042","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/gut.2005.068809","article-title":"Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis","volume":"55","author":"Ardizzone","year":"2006","journal-title":"Gut"},{"key":"2022080417290500900_CIT0043","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"2022080417290500900_CIT0044","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2022080417290500900_CIT0045","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1046\/j.1365-2141.1998.00812.x","article-title":"Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations","volume":"102","author":"Lancaster","year":"1998","journal-title":"Br J Haematol"},{"key":"2022080417290500900_CIT0046","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s002800050816","article-title":"Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine","volume":"42","author":"Erb","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"2022080417290500900_CIT0047","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00054725-200108000-00001","article-title":"An open-label pilot study using thioguanine as a therapeutic alternative in Crohn\u2019s disease patients resistant to 6-mercaptopurine therapy","volume":"7","author":"Dubinsky","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"2022080417290500900_CIT0048","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1046\/j.1365-2036.2003.01440.x","article-title":"6-Thioguanine\u2013efficacy and safety in chronic active Crohn\u2019s disease","volume":"17","author":"Herrlinger","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"2022080417290500900_CIT0049","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00042737-200301000-00011","article-title":"6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment","volume":"15","author":"Derijks","year":"2003","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2022080417290500900_CIT0050","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/j.1572-0241.2003.07413.x","article-title":"Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine","volume":"98","author":"Dubinsky","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"2022080417290500900_CIT0051","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0016-5085(03)00938-7","article-title":"6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients","volume":"125","author":"Dubinsky","year":"2003","journal-title":"Gastroenterology"},{"key":"2022080417290500900_CIT0052","doi-asserted-by":"crossref","first-page":"e0212157","DOI":"10.1371\/journal.pone.0212157","article-title":"Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: a systematic review","volume":"14","author":"Toksvang","year":"2019","journal-title":"PLoS One"},{"key":"2022080417290500900_CIT0053","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1097\/MIB.0000000000000869","article-title":"The prevalence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with thioguanine is not associated with clinically significant liver disease","volume":"22","author":"van Asseldonk","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2022080417290500900_CIT0054","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1080\/00365520701800266","article-title":"Histopathology of liver biopsies from a thiopurine-na\u00efve inflammatory bowel disease cohort: prevalence of nodular regenerative hyperplasia","volume":"43","author":"De Boer","year":"2008","journal-title":"Scand J Gastroenterol"},{"key":"2022080417290500900_CIT0055","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drudis.2017.08.008","article-title":"Finding hidden treasures in old drugs: the challenges and importance of licensing generics","volume":"23","author":"Simsek","year":"2018","journal-title":"Drug Discov Today"},{"key":"2022080417290500900_CIT0056","doi-asserted-by":"crossref","first-page":"9012","DOI":"10.3748\/wjg.v22.i40.9012","article-title":"Efficacy of thioguanine treatment in inflammatory bowel disease: a systematic review","volume":"22","author":"Meijer","year":"2016","journal-title":"World J Gastroenterol"},{"key":"2022080417290500900_CIT0057","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/FPC.0b013e328334338f","article-title":"Thiopurine pathway","volume":"20","author":"Zaza","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"2022080417290500900_CIT0058","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1172\/JCI16432","article-title":"CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes","volume":"111","author":"Tiede","year":"2003","journal-title":"J Clin Invest"},{"key":"2022080417290500900_CIT0059","first-page":"1207","article-title":"Relationship between metabolic fates and antitumor activities of thiopurines","volume":"23","author":"Elion","year":"1963","journal-title":"Cancer Res"},{"key":"2022080417290500900_CIT0060","first-page":"197","article-title":"Experimental, clinical, and metabolic studies of thiopurines","volume":"16","author":"Elion","year":"1962","journal-title":"Cancer Chemother Rep"},{"key":"2022080417290500900_CIT0061","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0006-2952(63)90012-1","article-title":"Potentiation by inhibition of drug degradation: 6-substituted purines and xanthine oxidase","volume":"12","author":"Elion","year":"1963","journal-title":"Biochem Pharmacol"},{"key":"2022080417290500900_CIT0062","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2036.2005.02583.x","article-title":"Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine","volume":"22","author":"Sparrow","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"2022080417290500900_CIT0063","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/apt.15402","article-title":"Real-life study of safety of thiopurine-allopurinol combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment","volume":"50","author":"Kreijne","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2022080417290500900_CIT0064","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.bcp.2013.06.002","article-title":"Mechanism of allopurinol induced TPMT inhibition","volume":"86","author":"Blaker","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"2022080417290500900_CIT0065","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1080\/00365521.2016.1216589","article-title":"Randomized clinical trial: a pilot study comparing efficacy of low-dose azathioprine and allopurinol to azathioprine on clinical outcomes in inflammatory bowel disease","volume":"51","author":"Kiszka-Kanowitz","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"2022080417290500900_CIT0066","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/clpt.1989.119","article-title":"Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism","volume":"46","author":"Lennard","year":"1989","journal-title":"Clin Pharmacol Ther"},{"key":"2022080417290500900_CIT0067","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/17425255.2021.1974398","article-title":"Understanding thiopurine methyltransferase polymorphisms for the targeted treatment of hematologic malignancies","volume":"17","author":"Franca","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2022080417290500900_CIT0068","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/0140-6736(93)93168-Z","article-title":"Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient","volume":"341","author":"McLeod","year":"1993","journal-title":"Lancet"},{"key":"2022080417290500900_CIT0069","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/0140-6736(93)93028-Y","article-title":"Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient","volume":"341","author":"Sch\u00fctz","year":"1993","journal-title":"Lancet"},{"key":"2022080417290500900_CIT0070","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0016-5085(00)70354-4","article-title":"Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn\u2019s disease and severe myelosuppression during azathioprine therapy","volume":"118","author":"Colombel","year":"2000","journal-title":"Gastroenterology"},{"key":"2022080417290500900_CIT0071","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/ecco-jcc\/jjz009","article-title":"Genotype-guided thiopurine dosing does not lead to additional costs in patients with inflammatory bowel disease","volume":"13","author":"Sluiter","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2022080417290500900_CIT0072","doi-asserted-by":"crossref","first-page":"e242","DOI":"10.1097\/MCG.0b013e3181d6baf5","article-title":"Influences of thiopurine methyltransferase genotype and activity on thiopurine-induced leukopenia in Korean patients with inflammatory bowel disease: a retrospective cohort study","volume":"44","author":"Kim","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"2022080417290500900_CIT0073","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/j.1440-1746.2009.05917.x","article-title":"Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease","volume":"24","author":"Takatsu","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"2022080417290500900_CIT0074","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00008571-199902000-00006","article-title":"The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations","volume":"9","author":"Collie-Duguid","year":"1999","journal-title":"Pharmacogenet Genom"},{"key":"2022080417290500900_CIT0075","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/ng.3060","article-title":"A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia","volume":"46","author":"Yang","year":"2014","journal-title":"Nat Genet"},{"key":"2022080417290500900_CIT0076","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/ng.3508","article-title":"NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity","volume":"48","author":"Moriyama","year":"2016","journal-title":"Nat Genet"},{"key":"2022080417290500900_CIT0077","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1200\/JCO.2014.59.4671","article-title":"Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia","volume":"33","author":"Yang","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022080417290500900_CIT0078","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.3748\/wjg.v20.i13.3534","article-title":"Pharmacogenetics of azathioprine in inflammatory bowel disease: a role for glutathione-S-transferase?","volume":"20","author":"Stocco","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2022080417290500900_CIT0079","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/ibd.20004","article-title":"Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease","volume":"13","author":"Stocco","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"2022080417290500900_CIT0080","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/MCG.0b013e31828b2866","article-title":"Deletion of glutathione-s-transferase m1 reduces azathioprine metabolite concentrations in young patients with inflammatory bowel disease","volume":"48","author":"Stocco","year":"2014","journal-title":"J Clin Gastroenterol"},{"key":"2022080417290500900_CIT0081","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jphs.2015.02.013","article-title":"The impact of glutathione S-transferase genotype and phenotype on the adverse drug reactions to azathioprine in patients with inflammatory bowel diseases","volume":"129","author":"Liu","year":"2015","journal-title":"J Pharmacol Sci"},{"key":"2022080417290500900_CIT0082","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3390\/genes10040277","article-title":"Azathioprine biotransformation in young patients with inflammatory bowel disease: contribution of glutathione-S transferase M1 and A1 variants","volume":"10","author":"Lucaf\u00f2","year":"2019","journal-title":"Genes"},{"key":"2022080417290500900_CIT0083","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.mimet.2016.07.017","article-title":"Microbial metabolism of thiopurines: a method to measure thioguanine nucleotides","volume":"128","author":"Movva","year":"2016","journal-title":"J Microbiol Methods"},{"key":"2022080417290500900_CIT0084","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/gutjnl-2015-310874","article-title":"Colonic microbiota can promote rapid local improvement of murine colitis by thioguanine independently of T lymphocytes and host metabolism","volume":"66","author":"Oancea","year":"2017","journal-title":"Gut"},{"key":"2022080417290500900_CIT0085","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.drudis.2018.09.001","article-title":"A well-tolerated and rapidly acting thiopurine for IBD?","volume":"24","author":"Florin","year":"2019","journal-title":"Drug Discov Today"},{"key":"2022080417290500900_CIT0086","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1097\/MIB.0b013e318281f28f","article-title":"Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients","volume":"19","author":"Chaparro","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"2022080417290500900_CIT0087","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/ibd.21221","article-title":"Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts","volume":"16","author":"Jharap","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"2022080417290500900_CIT0088","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s12876-020-01441-6","article-title":"Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom","volume":"20","author":"Bayoumy","year":"2020","journal-title":"BMC Gastroenterol"},{"key":"2022080417290500900_CIT0089","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/apt.15280","article-title":"Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies","volume":"50","author":"Simsek","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2022080417290500900_CIT0090","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/0003-4819-111-8-641","article-title":"6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity","volume":"111","author":"Present","year":"1989","journal-title":"Ann Intern Med"},{"key":"2022080417290500900_CIT0091","first-page":"106","article-title":"Malignant lymphomas in transplantation patients","volume":"1","author":"Penn","year":"1969","journal-title":"Transplant Proc"},{"key":"2022080417290500900_CIT0092","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"key":"2022080417290500900_CIT0093","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"2022080417290500900_CIT0094","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cgh.2014.05.015","article-title":"Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis","volume":"13","author":"Kotlyar","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022080417290500900_CIT0095","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00007890-197210000-00001","article-title":"Malignant tumors arising de novo in immunosuppressed organ transplant recipients","volume":"14","author":"Penn","year":"1972","journal-title":"Transplantation"},{"key":"2022080417290500900_CIT0096","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/bmb\/ldaa033","article-title":"Thiopurines and non-melanoma skin cancer: partners in crime in inflammatory bowel diseases","volume":"136","author":"Solitano","year":"2020","journal-title":"Br Med Bull"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjac004\/42333584\/jjac004.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/16\/7\/1177\/45250822\/jjac004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/16\/7\/1177\/45250822\/jjac004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T17:30:13Z","timestamp":1659634213000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/16\/7\/1177\/6505325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,12]]},"references-count":96,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,1,12]]},"published-print":{"date-parts":[[2022,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac004","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2022,1,12]]}}}